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1. Introduction 
Breast cancer is the most commonly diagnosed cancer in women worldwide and 
consequently has been extensively investigated in terms of histopathology, 
immunochemistry and familial history [1]. Fortunately, technological advances have 
enabled characterization of the molecular subtypes of breast cancer [2, 3] and this in turn has 
facilitated the development of molecularly targeted therapeutics for this disease.  
Profiling breast cancer with expression arrays has become common, and it has been 
suggested that the results from early studies will lead to understanding the molecular 
differences between clinical cases and allow individualization of care. Breast cancer may 
now be subclassified into luminal, basal, and ErbB2/HER2 subtypes with distinct differences 
in prognosis and response to therapy. These groups of tumors confirmed long-recognized 
clinical differences in phenotype, but added new knowledge regarding breast cancer 
biology. For example, the gene expression profiling revealed that within the estrogen 
receptor (ER)-positive tumors at least two subtypes, luminal A and luminal B, could be 
distinguished that vary markedly in gene expression and prognosis [3]. Conversely, 
hormone receptor–negative breast cancer comprised two distinct subtypes, the ErbB2 
subtype and the basal-like subtype [3, 4]. These subtypes differ in biology and behavior, and 
both show a poor outcome. Importantly a very similar classification of breast cancers has 
now been characterized using immunohistochemistry to analyze patterns of protein 
expression in tumor sections and suggesting that a few protein biomarkers can be used to 
stratify breast cancers into different groups that can be mapped to the subtypes outlined 
below [5-8]. 
Luminal breast cancers are the most common subtype of breast cancer. The luminal 
subtypes make up the hormone receptor–expressing breast cancers, and have expression 
patterns reminiscent of the luminal epithelial component of the breast [2]. These patterns 
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include expression of luminal cytokeratins 8/18, ER and genes associated with ER activation 
such as LIV1 and CCND1 (also known as cyclin D1) [2, 9]. Fewer than 20% of luminal 
tumors have mutations in TP53, and these tumors are often grade I [3, 9]. Within the luminal 
cluster there are at least two subtypes, luminal A and luminal B. Although both are 
hormone receptor expressing, these two luminal subtypes have distinguishing 
characteristics. Luminal A has, in general, higher expression of ER-related genes and lower 
expression of proliferative genes than luminal B [3, 4].  
The basal-like subtype of breast cancer was so named because the expression pattern of this 
subtype mimicked that of the basal epithelial cells of other parts of the body and normal 
breast myoepithelial cells [2]. These similarities include lack of expression of ER and related 
genes; low expression of ErbB2; strong expression of basal cytokeratins 5, 6, and 17; and 
expression of proliferation-related genes [2, 9]. Immunohistochemical profiling using tissue 
microarrays has identified that a group of tumors characterized by basal cytokeratin 
expression are also characterized by low expression of BRCA1 [10]. Basal-like tumors are 
more likely to have aggressive features such as TP53 mutations and a markedly higher 
likelihood of being grade III (P < 0.0001) than luminal A breast cancers (P < 0.0001) [3]. 
Finally, the other breast cancer subtype that has been identified is distinguished by 
amplification of the gene encoding the human epidermal growth factor receptor 2 
(ErbB2/HER2). The human ErbB/HER receptor family comprises four tyrosine kinase 
receptors (HER1/ErbB1, also termed the epidermal growth factor receptor (EGFR), 
HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4) that play important roles in the progression of 
various types of cancers, including breast, prostate, and colon cancer [11]. Deregulation of 
ErbB receptor signaling leads to enhanced cell proliferation, migration, and malignant 
transformation. Overexpression, amplification, or mutation of the ERBB2 gene occurs in 
approximately 20–30% of invasive breast cancers, and is associated with disease progression, 
poor prognosis, increased risk of metastases and shorter overall survival [12]. 
ErbB2-mediated signal transduction is believed to depend largely on heterodimerization 
with EGFR or ErbB3, and these heterodimers activate a signaling program that drives cell 
proliferation, resistance to apoptosis, loss of polarity, and increased motility and 
invasiveness [13, 14]. Trastuzumab is a humanized monoclonal antibody targeted against 
the extracellular portion of ErbB2. This is the first ErbB2-targeted agent to be approved by 
the United States Food and Drug Administration (FDA) for the treatment of both early stage 
and metastatic ErbB2-overexpressing (ErbB2 positive) breast cancers [15, 16]. Subsequently, 
lapatinib, an orally bioavailable small molecule dual ErbB2- and EGFR/HER1-specific 
tyrosine kinase inhibitor (TKI), received FDA approval in combination with capecitabine for 
patients with advanced ErbB2 positive breast cancer [17]. 
Although ErbB2-targeted therapies have had a significant impact on patient outcomes, 
resistance to these agents is common. In clinical trials, 74% of patients with ErbB2 positive 
metastatic breast cancer did not have a tumor response to first-line trastuzumab 
monotherapy [18] and 50% did not respond to trastuzumab in combination with 
chemotherapy [15]. These examples illustrate the problem that inherent (de novo) resistance 
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to ErbB2-targeted agents poses for effective treatment of ErbB2 positive breast cancer. 
Moreover, only approximately one-quarter of patients with ErbB2 positive metastatic breast 
cancer who were previously treated with trastuzumab achieved a response with lapatinib 
plus capecitabine [17]. These limitations have led to efforts to better understand the 
underlying cellular networks that confer resistance to these agents in order to better select 
patients who are most likely to benefit from specific therapies and to develop new agents 
that can overcome resistance.  
The goal of this review is to give a concise overview of current approaches in the field of 
phosphoproteomics and to show how a combination of several approaches can be used to 
obtain a more comprehensive understanding of a given signaling pathway. A number of 
proteomic approaches have been developed over the years to identify aberrantly activated 
kinases and their downstream substrates. Most often, phosphorylation is used as a surrogate 
for monitoring kinase activity in cells. In the past, kinases and their activities were generally 
studied on an individual basis using biochemical approaches. However, technological 
advances in the recent past have led to development of several high-throughput strategies to 
study the phosphoproteome. High-throughput technologies for monitoring phosphorylation 
events include array-based technologies such as peptide arrays [19-21], antibody arrays [22] 
and mass spectrometry [23, 24]. Quantitative phosphoproteomic profiling allows researchers 
to investigate aberrantly activated signaling pathways and therapeutic targets in cancers. 
Finally, phosphoproteomic approaches can not only assist in determining the appropriate 
therapeutic targets but also elucidate mechanisms such as off-target effects resulting from 
binding of inhibitors to unintended kinases/non-kinase proteins. Here, we will discuss some 
of the popular approaches to characterize the kinome and the phosphoproteome along with 
illustrative examples where such approaches have been employed for global analysis of 
breast cancer. 
2. Challenges of phosphoproteomics 
Phosphoproteomic analysis is plagued by the same challenges facing all proteomic 
experiments: complexity, dynamic range, and temporal dynamics. The true complexity of 
the phosphoproteome has yet to be determined, but the Phosphosite database 
(http://www.phosphosite.org) now lists 30 000 phosphorylation sites on 17 000 proteins, and 
this number is steadily increasing as each large-scale phosphorylation analysis continues to 
identify a large number of novel sites. With so many of the proteins in the cell being 
phosphorylated, the dynamic range of the phosphoproteome is similar to that of the 
proteome (i.e., 1x109), but is further increased by substoichiometric modification. In 
addition, the temporal dynamics of protein phosphorylation regulate the rapid activation 
and deactivation of cellular signaling networks, further complicating analysis of the 
phosphoproteome. So the challenge is not simply to identify and catalog all of the 
phosphorylation sites, but rather to identify the site, quantify the stoichiometry, and 
monitor the temporal change in phosphorylation in response to a variety of cellular 
perturbations. Performing this task on a large number of phosphorylation sites across a 
broad swath of the signaling network is especially challenging, but is required to 
understand the mechanisms by which protein phosphorylation controls cell biology 
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3. Mass Spectometry (MS)-based approaches 
Currently, the most powerful tool to interrogate the phosphoproteome is enrichment for 
phosphopeptides followed by reverse-phase liquid chromatography combined with tandem 
mass spectrometry (LC-MS/MS). When sample preparation and instrumentation are chosen 
appropriately, thousands of phosphorylation sites can be identified (Figure 1). Some 
research groups have already taken advantage of these methodologies for identifying 
proteins that could be useful therapeutic targets or novel molecular markers in breast cancer 
specimens. Many of these analyses have focused in tyrosine phosphorylation profiles due to 
the fact that approximately half of the tyrosine kinase complement of the human kinome is 
implicated in human cancers [4], and provides important targets for cancer treatment, as 
well as biomarkers for patient stratification. Recently, Chen et al. adapted LC-MS/MS 
technology to assess the tyrosine phosphorylation profile in the MCF10AT model of breast 
cancer progression [25]. This study identified and validated seven proteins, termed SPAG9, 
CYFIP1, RPS2, TOLLIP, SLC4A7, WBP2, and NSFLC1, to be authentic tyrosine kinase 
substrates. In addition, SPAG9, WBP2, TOLLIP, and NSFL1C were demonstrated to be 
authentic tyrosine phosphorylation targets of EGFR signaling, and differential expression of 
TOLLIP and SLC4A7 was subsequently validated in clinical breast cancer samples. 
Consistent with the MCF10AT model, more than 30% of the human breast cancer samples 
analyzed in this study displayed reduced expression of SLC4A7 compared with normal 
tissues. In contrast, only 25% of the samples showed increased levels of TOLLIP when 
normal cells become cancerous.  Moreover detection of aberrant expression of TOLLIP and 
SLC4A7 in pre-neoplastic lesions suggests that they represent potential biomarkers that 
could complement mammography and histopathology for screening and early detection of 
breast cancer [25]. 
Most recently, a number of reports have demonstrated the importance of EGFR signaling in 
breast cancer [26-28]. Hochgrafe et al. characterized the tyrosine kinase signaling networks 
associated with different breast cancer subgroups [27]. By using this approach in a panel of 
15 different breast cancer cell lines, the authors identified 544 phosphotyrosine sites in 
peptide sequences derived form 295 non redundant proteins, interestingly, 31 of these are 
novel tyrosine phosphorylation sites. Upon unsupervised hierarchical clustering using data 
for all tyrosine phosphorylated proteins, the 15 cell lines were clustered into two groups 
previously characterized as “basal” or “luminal” by transcript profiling [29]. Increased 
phosphorylation of several tyrosine kinases (i.e. Met, Lyn/Hck, EphA2, EGFR, and FAK) 
was characteristic of basal lines. In contrast, IGF1R/INSR, ErbB2, and ACK1 exhibited 
increased phosphorylation in luminal breast cancer cells. For all of the differentially 
phosphorylated kinases, increased phosphorylation was detected on sites that positively 
regulate kinase activity and downstream signaling. For example, Met Y1234, Lyn Y397, and 
FAK Y577 are activation loop sites [30], and phosphorylation of Y588 and Y594 in the 
juxtamembrane region of EphA2 is required for kinase activity [31]. In the case of EGFR and 
ErbB2, differential phosphorylation was predominantly on sites in the COOH-terminal tail 
that promote activation of the Ras/Raf/MEK/ERK pathway [32, 33]. A deeper analysis of the 
tyrosine phosphoproteome revealed a signature that characterizes the basal phenotype, and 
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identified a prominent Src family kinase (SFK) signaling network in basal breast cancer cells 
that extends not only downstream to canonical SFK substrates regulating cell adhesion and 
migration but also upstream to specific RTKs such as EGFR, ErbB2 and Met among others. 
Subsequent functional analyses determined that SFKs transmit pro-proliferative, pro-
survival and pro-mitogenic signals in these cells, and that Lyn is an important regulator of 
cell invasion. In addition, SFKs promoted tyrosine phosphorylation of specific RTKs in these 
cells, and this may attenuate cellular sensitivity to therapies directed against these receptors. 
Consequently, these findings provide important insights into the biology of basal breast 
cancers and have significant implications for the development of therapeutic strategies that 
target this subtype of breast cancer [27].  
A very elegant study performed by Zhang et al. analyzed the EGF induced protein 
phosphorylation events in the Human Mammary Epithelial Cell (HMMC) 184A1 [26]. In this 
report, a time course phosphorylation profile of 78 tyrosine phosphorylation sites on 58 
proteins was generated. For each phosphorylation site, a quantitative temporal 
phosphorylation profile was generated by comparing the relative ratios of peak areas for the 
iTRAQ marker ions in the MS/MS spectrum. Of the 58 proteins identified in this analysis, 52 
have been already associated with the EGFR signaling network, whereas the other six 
proteins have not been previously identified in either proteomic or biochemical analyses of 
EGFR signaling.  Contained in this group are phosphorylation sites on hypothetical protein 
FLJ00269, hypothetical protein FLJ21610, target of myb1-like 2 protein, and chromosome 3 
open reading frame 6. In addition to the six proteins that had not been previously 
characterized in the EGFR signaling network, the authors also identified several novel 
phosphorylation sites on proteins known to be in the network. The bioinformatic analysis of 
the data generated by this method self-organize into clusters of phosphorylation sites that 
correlate with well known signaling nodes reported in the literature (i.e. the 
Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways). In a related study, the same 
research group analyzed the EGF- and heregulin (HRG)-induced protein phosphorylation 
events that control cell migration and proliferation in the context of ErbB2 overexpression in 
HMMCs [34]. As a result of these analyses, 332 phosphorylated peptides from 175 proteins 
were identified, including 289 singly (tyrosine) phosphorylated peptides, 42 doubly 
phosphorylated peptides (21 tyrosine/tyrosine, 18 serine/tyrosine, and three 
threonine/tyrosine), and one triply phosphorylated peptide (tyrosine/tyrosine/tyrosine). A 
total of 20 phosphorylation sites were identified on EGFR, ErbB2, and ErbB3, including nine 
tyrosine and two serine sites on EGFR, eight tyrosine phosphorylation sites on ErbB2, and 
one tyrosine phosphorylation site on ErbB3. Of the 20 phosphorylation sites on EGFR family 
members, Y1114 on EGFR and Y1005 and Y1127 on ErbB2 represent novel sites that have not 
been previously described in the literature. To correlate signals with cell response, the 
authors also quantified proliferation and migration rates for these same cell states and 
stimulation conditions. Phenotypically, ErbB2 overexpression promoted increased cell 
migration, but had minimal effect on cell proliferation. More specifically, EGF stimulation of 
ErbB2-overexpressing cells promoted migration by the phosphorylation of proteins from 
multiple pathways (e.g., PI3K, MAPK, catenins, and FAK), whereas HRG stimulation of 
ErbB2-overexpressing cells activated only a very specific subset of proteins in the canonical 
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migration pathway, in particular FAK, Src, paxillin, and p130Cas. In contrast, proliferation 
was primarily driven by EGF stimulation, and was not affected by ErbB2 expression levels 
[34]. Finally, Kumar et al. significantly extend their previous analysis of ErbB2-mediated 
signaling and cell function by using a model that predicts ErbB2 effects on HMMCs 
behavior by using MS phosphotyrosine data sets [28]. The results of this research showed 
that ErbB2 overexpression in the presence of EGF, as discussed above, produced interesting 
signal network changes and increased cell migration but did not affect cell proliferation [34]. 
These findings both highlight previously identified elements in the ErbB2 signaling 
network, and suggest new pathways and targets critically implicated in ErbB2-mediated 
signaling and its effect on migration and proliferation. 
Although MS has proven to be an extraordinary tool for protein characterization, 
measurement of peptide intensities alone does not immediately provide quantitative 
information. There are several approaches to overcome this problem. Stable isotopes are 
incorporated either by metabolic labeling, as in the SILAC (stable isotope labeling with 
amino acids in cell culture) method, or by chemical derivatization (Figure 1) [35].  SILAC 
relies on metabolic incorporation of an isotopically labeled amino acid. Two groups of cells 
are grown in culture media that are identical except in one respect: the first media contains 
the ‘‘light’’ and the other a ‘‘heavy’’ form of a particular amino acid (for e.g. L-leucine or 
deuterated L-leucine). Through the use of special cell culture medium lacking the modified 
amino acids, the cells are forced to use the particular labeled or unlabeled form of the amino 
acid previously added to the medium. In each cell doubling, the cell population replaces at 
least half of the original form of the amino acid, eventually incorporating 100% of a given 
light or heavy form of the amino acid. A variety of amino acids are suitable in SILAC, 
including arginine, leucine, lysine, serine, methionine and tyrosine. The different cell line 
conditioned media can then be combined and run together in a single MS run. The 
advantages of SILAC include the fact that the labeling process is highly efficient, it does not 
require additional purifications to remove excess labeling reagent, nor does it involve multi-
step labeling protocols and the sample preparation bias introduced by the comparison of 
two separate preparation steps is avoided. As well, SILAC allows the experimenter to use 
any method of protein or peptide purification (after enzymatic digestion) without 
introducing error into the final quantitative analysis. In one study, SILAC was utilized to 
examine differential membrane expression between normal and malignant breast cancer 
cells [36]. Approximately 1,000 proteins were identified with more than 800 of these proteins 
being classified as membrane or membrane-associated. Although the majority of the 
proteins remained unchanged when compared with the corresponding normal cells, a 
number of proteins were found upregulated or down-regulated by greater than 3-fold. 
A few years ago, Bose et al. described a quantitative proteomic analysis to study ErbB2 
signaling by using SILAC in 3T3 cells ectopically expressing ErbB2 [37]. By using this 
methodology, the authors identified a panel of 198 proteins that displayed increased 
phosphorylation levels and a group of 81 proteins that showed decreased phosphorylation 
levels merely by ErbB2 overexpression. The list of proteins that showed high 
phosphorylation levels included several well known ErbB2 downstream effectors and 
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modulators of pro-survival, anti-apoptotic and proliferative pathways, such as PLCγ1, the 
regulatory and catalytic subunits of PI3K (p85β, p85α, and p110β), the Src family member 
Fyn, RasGAP, and HSP90. Importantly, several known EGFR signaling proteins, which had 
not been previously implicated in ErbB2 signaling, were also identified, including Stat1, 
Dok1, and δ-catenin. The 81 proteins that displayed decreased phosphorylation levels in 
3T3-ErbB2 cells included FAK, p130-Cas/BCAR1, and caveolin 1 among others.  In this 
study, the effect of the EGFR and ErbB2 selective tyrosine kinase inhibitor (TKI), PD168393, 
was also quantified, the results showed that 83 of the 198 proteins that displayed increased 
phosphorylation when ErbB2 was overexpressed were inhibited by 100 nM of PD168393 
(>1.5-fold), and 27 proteins showed a smaller degree of inhibition (1.3- to 1.5-fold), 
suggesting that 110 of these 198 proteins are affected by this TKI. Under these conditions, 79 
proteins were not affected by PD168393, including Fyn and three subunits of PI3K. This 
observation raises the question of whether different arms of the ErbB2 signaling pathway 
have differential inhibitor sensitivity. To validate the relevance of these proteins to ErbB2 
signaling in a more realistic setting, the authors used the ErbB2 positive breast cancer cell 
line BT-474. As expected, PD168393 also inhibited the phosphorylation of PLCγ1 and Stat1 
in BT-474 cells, supporting the idea that phosphoproteins identified by performing SILAC 
on 3T3-ErbB2 cells may be applicable to other ErbB2-overexpressing cell lines. 
Although SILAC has proven to be a very powerful method to dissect signaling in tumor cell 
lines, metabolic labeling has a major limitation. Whereas proteins in cultured cells can be 
readily labeled, those in living organisms cannot. Approaches have been developed to 
metabolically label worms, flies [38] and even mice [39] and rats [40], but human tissues 
have to this day remained 'unlabelable'. When applying proteomics to tumor biology, it is 
imperative to quantify a representative number of proteins, to obtain reproducible results 
and to study cancer-relevant proteins of low abundance. Ishihama et al. have tried to solve 
this problem by adding labeled cultured cells to the tissue samples [41]. However the 
comparison of a single cell line with a whole tissue context has several limitations. More 
recently, Geiger et al. mixed labeled protein lysates from several previously established 
cancer-derived cell lines, which together are more representative of the full complexity of a 
tissue proteome than a single cell line, thereby increasing accuracy [42]. Initially, they 
SILAC-labeled the breast cancer cell line HCC1599 and mixed the lysate with the lysate of 
mammary carcinoma tissue from an individual with grade II lobular carcinoma. Although 
they were able to quantify 4,438 proteins at least once in triplicate analysis, the ratio 
distribution was broad and bimodal, containing 755 proteins with more than fourfold higher 
expression in the tumor compared to the cell line. Next, they selected four breast cancer cell 
lines differing in origin, stage, ER and ErbB2 expression; and this superset of SILAC-labeled 
cell lines that more accurately representing the tissue was used for further analysis. The 
comparison of the tumor proteome with this “super-SILAC” mix, drastically improved the 
quantification accuracy. The distribution was unimodal and 90% of quantified proteins were 
within a fourfold ratio between the tumor and the super-SILAC mix (3,837 of 4,286 
quantified protein groups). Furthermore, the quantitative distribution was much narrower, 
with 76% of the proteins in the carcinoma and the super-SILAC mix differing by only 
twofold or less. Although super-SILAC has not been used to analyze the tumor 
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phosphoproteome yet, the results of this research accurately quantified more than a 
hundred protein kinases despite their low abundance. Among them were ErbB2, EGFR, 
AKT, Pak1 and Pak2 and nine members of the MAPK cascade, all representing pathways 
central to malignancy. At first view, this new method has great potential to expand the use 
of accurate relative proteomic quantitation methods to study molecular aspects of tumor 
biology and perhaps as a tool for candidate biomarker discovery, so it is conceivable that it 
will likely become a valuable tool for understanding the molecular and mechanistic aspects 
of phosphorylation in tumor samples.  
As described above, quantitative MS-based phosphoproteomics has been applied to identify 
oncogenic kinases which may serve as potential drug targets. To validate this hypothesis, 
cells are often treated with selected kinase inhibitors with the goal of altering cellular 
phenotype, but it is often difficult to establish whether the effect was due to on or off-target 
effects of the compound. In order to determine the mechanism of action, it may be necessary 
to quantify the specificity of the inhibitor. Two groups have pioneered the use of 
immobilized kinase inhibitors with broad specificity to enrich a substantial subset of protein 
kinases from total cell lysates followed by quantitative mass spectrometry. Daub et al. 
developed a kinase inhibitor pull-down technique in combination with phosphoproteomics 
to map and quantify more than one thousand phosphorylation sites on human protein 
kinases arrested in S- and M-phase of the cell cycle [43]. Researchers at Cellzome employed 
KinobeadsTM to enrich protein kinases and then performed competition-based assays using 
specific kinase inhibitor drugs such as imatinib (Gleevec), dasatinib (Sprycel) and bosutinib 
in BCR-Abl positive K562 cells [44]. Recently, Zhang et al. modified this approach in order 
to develop more potent inhibitors of the kinase AXL, which has an important role in 
mediating breast cancer cell motility and invasivity [45]. In this study, the authors used a 
chemical library of kinase inhibitors in order to identify small molecular inhibitors with 
selective activity on the AXL tyrosine kinase, the chemical compound NA80x1which has 
previously been reported to have inhibitory activity against Src kinase [46], inhibited AXL 
kinase activity in a dose-dependent manner, with an IC50 of 12.67 ± 0.45 μmol/L. Then, 
NA80x1 and a structurally similar, but much more potent inhibitor of Src and Abl kinases 
termed SKI-606, were chemically modified and attached to an affinity purification resin. To 
identify the specific targets (and some other off-targets) of these inhibitor derivatives, SILAC 
labeled proteins from the breast cancer cell line Hs578T were used for in vitro association 
experiments with the immobilized chemical compounds. The protein eluates from the 
respective affinity purifications were mixed and digested, and the resulting peptide 
fractions were analyzed by MS. In total, 146 different proteins were identified with at least 
two unique peptides in the MS experiments. Among them, 43 proteins were found to 
specifically bind to the immobilized compounds and 32 were kinases. In addition to known 
targets such as Src/Abl family kinases Src, Lyn, Arg, and the RTK AXL, which was 
functionally characterized as a cellular target in this study, a variety of other inhibitor-
interacting proteins were identified, including eight more tyrosine kinases (such as FAK and 
four Eph receptor kinase family members) as well as nine members from the STE group of 
kinases involved in mitogen-activated protein kinase (MAPK) signaling (including six 
MAP4K/STE20 kinase family members and two MAP2K family members). This study is a 
 
Phosphoproteomics for the Mapping of Altered Cell Signaling Networks in Breast Cancer 215 
clear example of how MS can help to identify off-targets of small molecular kinase inhibitors 
in order to develop more specific and potent chemicals for cancer therapies.   
 
Figure 1. Mass Spectometry based approaches. The upper panel shows the pipelines of a prototypical 
proteomics experiment. Proteins are extracted from a biopsy or tumor sample and digested with trypsin 
to obtain peptides. The resulting peptides are resolved by reverse phase liquid chromatography (LC) 
and subsequently, analyzed by tandem mass spectrometry (MS/MS). Finally, the matched peptides 
allow the identification of the proteins using databases. The lower panel shows the schematic outline of 
the SILAC method. Separate cultures of cells are grown in normal medium (12C6-arginine) or in 
medium containing arginine labeled at all six carbons with 13C (13C6-arginine). The cells in normal 
medium are left unstimulated whereas cells in the 13C-arginine medium are stimulated with an agent 
that activates signaling. The cells are harvested and equal amounts of lysate protein mixed together. In 
most cases, steps to enrich phosphoproteins and/or phosphopeptides after trypsin digestion are needed 
to detect low-abundance phosphopeptides. The peptides are resolved by LC-MS/MS and the data are 
used for automated database searching to identify peptides (and their corresponding protein) and to 
detect phosphopeptides. 
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4. Protein microarray approaches (non-MS) 
To monitor previously identified phosphorylation sites, the combination of phosphospecific 
antibodies and western blotting has been the gold standard. However, until recently the 
limited throughput of this approach, with only one phosphorylation site investigated at a 
time, has driven the development of other, high-throughput approaches.  
Arrays using phosphospecific antibodies to investigate phosphorylation sites have been 
developed [47, 48] and used to interrogate dozens of phosphorylation sites simultaneously 
[49]. As this technology requires antibodies with high-affinity and specificity, currently only 
a limited number of phosphorylation sites can be analyzed [50]. However, further 
development might lead to an even broader application of microarray technology for 
phosphoprotein studies. 
Protein microarray formats can be divided into two major classes: forward phase arrays and 
reverse phase arrays (Figure 2) [51]. In a forward phase array, each spot contains one type of 
immobilized capture molecule, usually an antibody. Each array is incubated with one test  
 
Figure 2. Protein microarray platforms. Forward phase arrays (top) immobilize a bait molecule such as 
an antibody designed to capture specific biotynilated proteins representing a specific treatment or 
condition. In this specific case, the bound analytes are detected by fluorescently labeled biotin. Reverse 
phase arrays immobilize the test sample analytes on the solid phase. An analyte specific labeled ligand 
(e.g., antibody; lower left) is applied in solution phase. Bound antibodies are detected by signal 
amplification (lower right). 
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sample such as a cellular lysate or serum sample representing a specific treatment condition, 
and multiple analytes from that sample are measured simultaneously. In contrast, the 
reverse phase array format immobilizes an individual test sample in each array spot, in a 
way that this array is comprised of hundreds of different patient samples or cellular lysates. 
In the reverse phase array format, each array is incubated with one detection protein (e.g., 
antibody), and a single analyte endpoint is measured and directly compared across multiple 
samples [47, 51-55].  
5. Forward phase protein arrays 
The most popular class of forward phase protein arrays in cancer research is the antibody 
array. A common application of antibody arrays is the identification of biomarkers or 
molecules that are potentially valuable for diagnosis or prognosis or as surrogate markers of 
drug response. The multiplex capability of antibody arrays allows the efficient screening of 
many marker candidates to reveal associations between proteins and disease states or 
experimental conditions. Multiplexed measurements also allow the evaluation of the use of 
multiple markers in combination. The use of combinations of proteins for disease 
diagnostics may produce fewer false positive and false negative results as compared with 
tests based on single proteins. Antibody microarrays, by increasing the number of proteins 
that can be conveniently measured in clinical samples, could more significantly take 
advantage of the benefit of using combined markers in diagnostics. Other example 
applications of antibody microarrays in cancer research are to evaluate the coordinated 
changes of members of signaling pathways or to measure changes in expression levels of a 
class of proteins, such as angiogenesis factors. 
Only a few studies using antibody arrays for breast cancer research have been reported. One 
of the first studies was performed by Hudelist et al., who employed a high-throughput 
protein microarray system which contains 378 well characterized monoclonal antibodies 
printed at high density on a glass slide in duplicate in order to compare the gene expression 
pattern of malignant and adjacent normal breast tissue in a patient with primary breast 
cancer [56]. Using this technique, the authors identified a number of proteins that show 
increased expression levels in malignant breast tissues such as casein kinase Iε, p53, annexin 
XI, CDC25C, eIF-4E and MAP kinase 7. The expression of other proteins, such as the 
multifunctional regulator 14-3-3e was found to be decreased in malignant breast tissue, 
whereas the majority of proteins remained unchanged when compared to the corresponding 
non-malignant samples. Moreover, the protein expression pattern was corroborated by 
immunohistochemistry, in which antibodies against 8 representative proteins known to be 
involved in carcinogenesis were employed in paraffin-embedded normal and malignant 
tissue sections deriving from the same patient. In each case, the results obtained by IHC 
matched the data obtained by antibody microarray system.  In another report [57], 224 
antibodies revealed proteins that are related to doxorubicin therapy resistance in breast 
cancer cell lines. A decrease in the expression of MAP kinase-activated 
monophosphotyrosine, cyclin D2, cytokeratin 18, cyclin B1 and heterogeneous nuclear 
ribonucleoprotein m3-m4 was found to be associated with doxorubicin resistance. Other 
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recent investigations helped identify a marker involved in invasion (interleukin (IL)-8) [58]. 
Studying the serum proteome from metastatic breast cancer patients and healthy controls 
with recombinant single-chain variable fragment (scFv) microarrays [59], breast cancer was 
identified with a specificity and sensitivity of 85% on the basis of 129 serum analytes. 
Although a number of companies have already developed phospho-antibody arrays for 
breast cancer research, there are only a few reports of the use of this technology in breast 
cancer. In 2008, Eckestein et al. [60], studied the cellular mechanisms of resistance to 
cisplatin using MCF-7 cells as a model system.  Cisplatin-resistant MCF-7 breast cancer cells 
were selected by exposure to sequential cycles of cisplatin that mimic the way the drug is 
used in the clinic. To investigate the phosphorylation status of the EGFR receptor family, a 
phosphoreceptor tyrosine kinase (phospho-RTK) array was used. In this assay, monoclonal 
capture antibodies, specific for a variety of RTKs, were spotted in an array format, and 
phosphorylation of EGFR family members was subsequently detected by a pan anti-
phosphotyrosine antibody conjugated to horseradish peroxidase. In nonresistant cells the 
EGFR was phosphorylated at a low level. In contrast, in cisplatin resistant MCF-7 cells both the 
EGFR and ERBB2 receptors were strongly phosphorylated. The phospho-RTK array detected 
very low ErbB3 and ErbB4 phosphorylation in both MCF-7 and cisplatin resistant MCF-7 cells, 
suggesting, that these receptor subtypes are not activated in cisplatin-resistant breast cancer 
cells. By using similar arrays, the authors examined the Ras/Raf/MEK/ERK, PI3K/AKT, JNK 
and p38 signaling pathways, which are downstream effectors of EGFR in a number of cell 
systems. The analysis of these pathways showed that the Ras/Raf/MEK/ERK and PI3K/AKT 
pathways are hyperactive in the cisplatin-resistant breast cancer cells, whereas the JNK and 
p38 pathways were not affected. Similarly, this study shows that cisplatin-resistant breast 
cancer cells have an inactivation of the p53 pathway and display high levels of BCL-2. A 
transcriptional profile of the cisplatin-resistant breast cancer cells also showed that these cells 
have an upregulation of the amphiregulin gene, the expression and secretion of this protein is 
also elevated and this mechanism creates an autocrine loop that confers resistance to cisplatin.  
A more recent study using this technology showed that activation of the PI3K-AKT pathway 
in tumors is modulated by negative feedback, including mTORC1-mediated inhibition of 
upstream signaling [61]. The authors clearly demonstrate that AKT inhibition induces the 
expression and phosphorylation of multiple receptor tyrosine kinases in a panel of different 
breast cancer cell lines. The results of this research suggest that receptor activation of PI3K-
AKT causes AKT-dependent phosphorylation of FOXO proteins, which downregulate the 
expression of some of the receptors that are tightly coupled to PI3K, including ErbB3, IGF1R, 
and IR. In addition, AKT activation leads to activation of TORC1 and S6K, which feedback 
inhibits IRS1 expression and other non defined regulators of receptor signaling, resulting in 
down modulation of the signaling pathway. Thus, AKT inhibition will result in activation of 
FOXO-dependent transcription of receptors and inhibition of S6K-dependent inhibition of 
signaling with resultant activation of multiple receptors. The downstream effects of AKT 
will be suppressed, but other RTK-driven signaling pathways will be activated. In contrast, 
TORC1 inhibition blocks S6K-dependent feedback, activates IGF and ErbB kinases, but not 
their expression, and, thus, activates both AKT and ERK signaling. These findings have 
important basic and therapeutic implications.  
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6. Reverse phase protein arrays 
Probing multiple arrays spotted with the same lysate concomitantly with different 
phosphospecific antibodies provides the effect of generating a multiplex readout. The utility 
of reverse phase protein microarrays lies in their ability to provide a map of known cell 
signaling proteins. Identification of critical nodes, or interactions, within the network is a 
potential starting point for drug development and/or the design of individual therapy 
regimens [62, 63]. The array format is also amenable to extremely sensitive analyte detection 
with detection levels approaching attogram amounts of a given protein and variances of less 
than 10% [51, 64]. Detection ranges could be substantially lower in a complex mixture such as 
a cellular lysate; however, the sensitivity of the reverse phase arrays is such that low 
abundance phosphorylated isoforms can still be measured from a spotted lysate amount of 
less than 10 cell equivalents. This level of sensitivity combined with analytical robustness is 
critical if the starting input material is only a few hundred cells from a biopsy specimen. Due 
to all this advantages, the reverse phase protein array has demonstrated a unique ability to 
analyze signaling pathways using small numbers of cultured cells or cells isolated by laser 
capture microdissection from human tissue procured during clinical trials [47, 53, 54, 65]. 
In a landmark study, Boyd et al. investigated how signaling pathways are differentially 
activated in different breast cancer subtypes [66]. In this study, the phosphorylation status of 
100 proteins was examined in a panel of 30 different breast cancer cell lines. These cell lines 
have previously been classified into the three major molecular subtypes using a combination 
of gene expression data and ErbB2 status [67]. Briefly, cell lines were assigned to luminal or 
basal-like classes using gene expression data, and ErbB2 amplification status was assigned 
by means of quantitative reverse transcription to identify cell lines with more than four 
copies of the 17q12-q21 locus. Then, the phosphorylated protein status from the 30 breast 
cancer cell lines was analyzed by reverse phase protein arrays. In order to reduce 
dimensionality of the data and find patterns that might be related to the differential activity 
of signaling pathways in particular subtypes of breast cancer, the principle component 
analysis (or PCA, which convert a set of observations of possibly correlated variables into a 
set of values of linearly uncorrelated variables called principal components) was used. The 
results of this analysis showed that the global proteomic signature determined by this 
method largely separates basal-like cell lines from ErbB2 amplified and luminal cell lines 
along the second principal component. Also, with the exception of the ErbB2-amplified line 
BT474, the majority of the luminal lines are separated from the ErbB2 lines. This analysis 
suggests that the phosphorylated protein end points in this analysis are significantly 
correlated because the first three principal components can account for 61% of the variance 
in the data and also that distinct pathways may be activated in the different 
subtypes. Moreover, this analysis suggests that specific pathway activation events may be 
present in the different molecular subtypes. In particular, basal-like lines were found to be 
distinct from luminal and ErbB2-amplified lines in having low levels of pPTEN and high 
levels of total EGFR, pPyk2 Y402, and pPKC-α S567. ErbB2-amplified cell lines were distinct 
from the other subtypes in having high levels of pERBB3, pFAK, and pEGFR Y1173, and 
luminal cell lines were distinct in having higher levels of phosphorylation of p70S6K S371 
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and A-RAF S299. In addition, this analysis revealed patterns of pathway activation that are 
not obvious from published gene expression analyses. In particular, basal-like cell lines were 
found to have high levels of phosphorylation of non-receptor tyrosine kinases, such as c-Abl 
and Pyk2, and in addition showed generally high levels of ERK1/2 phosphorylation and 
high total EGFR expression. In contrast, ErbB2-amplified cell lines were found to have high 
levels of phosphorylation of components of the EGFR pathway (e.g., Shc, ErbB3, EGFR), as 
well as other receptor tyrosine kinases (e.g., c-MET). Finally, luminal cell lines that do not 
have apparent amplification of ErbB2 showed generally higher levels of activation of 
downstream signaling pathway components in the AKT/mTOR pathway (e.g., p70S6K). 
A potentially important application of reverse phase protein array technology is the more 
personalized administration of targeted therapies based on the signaling status of a given 
patient's tumor. The assumption is that if a patient's tumor is addicted to the continued 
activation of a particular pathway for continued growth and survival [68], then 
phosphorylation at key nodes in that pathway may serve as hallmarks, indicating the 
presence of an activated pathway and the potential for therapeutic intervention with 
inhibitors targeting that pathway. Similarly, PI3K is a key transducer of growth factor 
signals from receptor tyrosine kinases, as well as a frequently mutated oncogene, suggesting 
that PI3K inhibitors might have beneficial effects in treating cancers driven by pathologic 
alterations of this pathway [69]. The results reported by Boyd et al., suggest that activation 
of these pathway modules occur in a subtype-specific manner and can provide the basis for 
therapeutic intervention. If this is true, basal tumors, which display high levels of EGFR, 
activated ERK1/2, and phosphorylation of Src-activated effector kinases, such as c-Abl and 
Pyk2 would be potential candidates for combined therapies with antibodies and/or small 
molecule inhibitors used in clinical trials. These findings also highlight the potential utility of 
reverse phase protein arrays in confirming pathway modulation upon therapeutic intervention 
and applications in examining pharmacodynamic biomarkers of drug response. For example, 
it is well documented that an inhibitor of all isoforms of the class I catalytic subunit of PI3K, 
GDC-0941, results in potent and selective inhibition of multiple nodes in the PI3K/AKT 
pathway and, thus, that reverse phase protein arrays might have utility monitoring surrogate 
markers of compound activity. Conversely, the results of this study also showed that a 
selective MEK inhibitor results in potent down-regulation of pERK1/2 and actually increases 
signaling through the PI3K/AKT axis. This result highlights the fact that signaling pathways 
are dynamically linked networks and that perturbations in one pathway may have unforeseen 
consequences on interacting pathways that may affect response to therapeutic agents [70].  
In a more recent study, Iadevaia et al. used a reverse-phase protein array to measure the 
transient response of the MDA-MB-231 breast cancer cell line after stimulation by insulin-
like growth factor (IGF-1) [71]. The experimental results showed that when active, IGFR 
propagates the signal downstream through the Ras/Raf/MEK/ERK (MAPK) and 
phosphoinositide-3-kinase/AKT (PI3K) signaling pathways. The signals from the MAPK and 
PI3K cascades are routed to the mTOR pathway through tuberous sclerosis (TSC2) 
inactivation. Phosphorylated mTOR activates p70S6K, which inactivates the insulin receptor 
substrate (IRS-1) through a negative feedback loop.   
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The experimental results indicate that combined inhibition of the MAPK and PI3K/AKT 
pathways optimally inhibited the signaling networks and decreased cell viability. In 
contrast, combined inhibition of the MAPK and mTOR cascades led to significant activation 
of p-AKT and increased cell viability. Although several other kinases and pathways may 
potentially regulate the viability of the MDA-MB-231 cells, the experimental results 
indicated that simultaneous inhibition of the MAPK and PI3K/AKT pathways was sufficient 
to significantly reduce cell proliferation. The procedure is currently being used to identify 
and validate drug combinations that can inhibit aberrant networks in a panel of human 
cancer cell lines. Figure 3 summarizes some of the deregulated signaling pathways 
described by the use of Phosphoproteomics.  
 
Figure 3. Altered signaling pathways in breast cancer. This interaction map was created in the String 
9.0 program (http://string-db.org) and summarizes some of the most commonly affected signaling 
pathways in breast cancer. Predicted functional links, consist of different colored lines: one color for 
each type of evidence. In this specific case, pink lines represent experimental evidence, blue lines 
represent interactions already published in databases and green lines text data mining. 
Oncogenomics and Cancer Proteomics –  
Novel Approaches in Biomarkers Discovery and Therapeutic Targets in Cancer 222 
7. Clinical implications 
Cancer is among the leading causes of death worldwide. Therefore, the design of effective 
strategies to successfully implement personalized cancer medicine in clinical practice needs 
to face substantial challenges in the future. One of the biggest challenges in cancer research 
is the fact there is currently an insufficient number of effective rationally targeted drugs to 
implement this strategy broadly, at the time of this review, at least 50 distinct selective 
kinase inhibitors had been developed to the level of a phase I clinical trial, some of them 
have already been tested in breast cancer patients and it is expected that many more will be 
developed as cancer phosphoproteome analysis efforts continue to identify additional 
potential targets (Table 1).  
 
Kinase Alteration Therapeutic Agent Reference 
Receptor Tyrosine Kinases   
EGFR Amplification, mutations gefitinib, erlotinib [72] 
ErbB2/Her2 Amplification lapatinib, trastuzumab [73] 
MET Amplification 
PF2341066, XL184, 
SU11274 
[74] 
FGFR2 Amplification, mutations PKC412, BIF1120 [75] 
AXL Increased activation R428 [76] 
IGF1R/INSR Overexpression BMS-754807 [77] 
EphA2 Overexpression None available  
Non Receptor Tyrosine 
Kinases 
   
Ack1 Increased activation None available  
FAK Overexpression None available  
Src/Lyn/Hck Overexpression dasatinib, AZD05030 [78] 
Serine/Threonine Kinases    
PI3K Mutations BEZ235 [79] 
mTOR Increased activation everolimus [80] 
PLK Overexpression GSK461364 [81] 
Aurora Kinases A and B Overexpression MK5108 [82] 
Raf Increased activation sorafenib [83] 
MEK Increased activation PD0325901 [84] 
ERK1/2 Increased activation None available  
Pak1 
Amplification, 
overexpression 
None available  
Table 1. Oncogenic Kinases as Therapeutic Targets in Breast Cancer.   
The current phosphoproteomic goals imply the identification of phosphoproteins, mapping 
of phosphorylation sites, quantitation of phosphorylation under different conditions, and 
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the determination of the stoichiometry of the phosphorylation. In addition, knowing when a 
protein is phosphorylated, which kinase/s is-are involved, and how each phosphorylation 
fits into the signaling network, are also important challenges for researchers in order to 
understand the significance of different biological events. The new phosphoproteomic 
technologies are fundamental for cataloguing all this information, and it is heading towards 
the collection of accurate data on phosphopeptides on a global scale. In addition, the 
possible difficulties to get sufficient amount of specific phosphorylated proteins of specific 
low abundant protein-kinases in vivo which might limit the usability of the 
phosphoproteome analysis, must be pointed out. The concept of personalized cancer 
medicine also has significant implications for the drug development industry, which is 
beginning to recognize and appreciate the need to alter the current business model for drug 
development and clinical testing. Moreover, the clinical success of such kinase inhibitors as 
imatinib, erlotinib, and lapatinib has validated this strategy and has prompted a virtual 
explosion in the development of additional kinase inhibitors for cancer therapy. 
Importantly, though, with these successes has also come the realization that these agents are 
generally effective for a relatively small subset of treated patients, often defined by a 
common genomic, proteomic and/or phosphoproteomic denominator present within the 
tumor cells. Such findings have highlighted the potential importance of identifying defined 
patient subpopulations before treatment with kinase inhibitors to optimize clinical 
outcomes. 
Finally, it is important to state that to develop clinical proteomic applications using the 
identified proteins and phosphoproteins, collaboration between research scientists, 
clinicians and diagnostic companies, and proteomic experts is essential, particularly in the 
early phases of the biomarker development projects. The proteomics modalities currently 
available have the potential to lead to the development of clinical applications, and 
channeling the wealth of the information produced towards concrete and specific clinical 
purposes is urgent. 
8. Concluding remarks 
Cancer has been described as both a proteomic and a genomic disease [66]. Only those 
genetic defects creating a survival advantage increase the tumorigenic potential and are 
reflected in an altered functional state [19, 67]. Thus, the current challenges of cancer 
treatment, e.g. why do some patients respond to cancer drugs, while others do not, can only 
be answered with comprehensive efforts and by integrating knowledge on genetic and 
chromosomal aberrations, clinical data, IHC, and quantitative protein profiling. 
Phosphoproteomics has played a significant role in our ability to understand molecular 
mechanisms that govern human cancers. Various technological platforms are now available 
for phosphoproteomic studies enabling us to address different aspects of tumor biology 
governed by phosphorylation-mediated signaling pathways. These studies have clearly 
taken us beyond looking at mutations or other genetic variations commonly observed in 
cancers and are providing us insights into functional consequences of these changes in 
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conferring survival advantages to cancer cells. Such studies are already being used as the 
basis for determining therapeutic options. With an ever increasing list of kinase inhibitors 
being developed by pharmaceutical companies, such strategies have become vital not only 
to determine the targets of these inhibitors but also to study their off-target effects. We 
foresee phosphoproteomics emerging as a vital technique in clinical research to assist in 
diagnosis, prognosis and treatment of cancers. The major challenge ahead is to develop this 
technology further to make it amenable for use in the clinic with as few sample processing 
steps as possible. 
There are several issues, however, that must be carefully and promptly addressed if we are 
going to fulfill the dream of bringing individualized cancer care closer to reality. First of all, 
we must acknowledge the value of long-term research and provide the appropriate legal 
and ethical framework to encourage the collaboration among all the stakeholders in the 
cancer ordeal. Bridging the gap between basic and clinical research, facilitating the 
engagement of the industry, creating new infrastructures and bio banks, as well as the 
creation of innovative clinical trials are among the items that require urgent action. The aim 
of cancer research is to improve the life expectancy and quality of life of patients and we 
must make every effort to coordinate current activities in order to achieve this goal. 
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